While many strides have been made in the study of human immune responses, numerous knowledge gaps still
remain. Many infections and immune-mediated diseases are localized to specific tissues, or organs but little is
known about tissue/organ-specific immunity. A major overall goal of this CCHI program to this end is to
understand memory CD8 T cells differentiation in the blood, tissues and organs. We have added Dr. Donna
Farber to our CHHI-EVC team this cycle. She has established a unique human tissue resource enabling
acquisition of blood and various tissues from deceased organ donors, we will therefore analyze virus-specific
memory CD8 T cells in various tissues of deceased organ donors and address questions regarding the anatomic
distribution and the epigenetic, transcriptional and phenotypic profile of virus-specific CD8 T cells elicited by live-
attenuated virus vaccines and with minimal risk of antigenic re-exposure. The second major goal of this program
is to elucidate the molecular mechanisms of “trained immunity” after YFV vaccination and viral infection to and
harness this knowledge for future development of new classes of vaccines and immunotherapies. We will
address the following questions. To what extent is so called “innate memory” caused by the effects of an ongoing
adaptive immune response (for example, via paracrine signaling), versus a cell intrinsic property of innate cells,
similar to the classic phenomenon of immune memory exhibited by memory T or B cells? Is there an enhanced
response of DCs and monocytes, (similar to a memory response in the adaptive immune system), during
secondary vaccination or infection? If so, what are the cellular and molecular mechanisms involved? Finally, the
third overall goal is to identify signaling and transcription factor (TF) networks associated with T memory cell
differentiation and survival and quantify how these networks change with age. This will be achieved in the
following projects: Project 1: Immune memory (Ahmed, Hellerstein, Farber); Project 2: Innate immunity
(Pulendran, Hellerstein), and Project 3: Immune senescence (Goronzy, Greenleaf). Supported by the following
Core A: Adminstration (Ahmed); Core B: Single cell and integrative genomics (Bosinger, Greenleaf); Core C:
Clinical and biostatistical (Edupuganti, Kulkanya, Yu).
Public Health Relevance Statement
The studies proposed in this CCHI application on human CD8 T cell memory in blood and tissues, on
mechanisms of trained innate immunity, and on molecular mechanisms of T cell aging will provide a
framework for the rational design of vaccines that elicit long-term protective immunity.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
01-September-2003
Project End Date
30-April-2025
Budget Start Date
01-August-2023
Budget End Date
30-April-2025
Project Funding Information for 2023
Total Funding
$1,735,875
Direct Costs
$1,347,460
Indirect Costs
$388,415
Year
Funding IC
FY Total Cost by IC
2023
NIH Office of the Director
$1,735,875
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U19AI057266-20S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U19AI057266-20S1
Patents
No Patents information available for 3U19AI057266-20S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U19AI057266-20S1
Clinical Studies
No Clinical Studies information available for 3U19AI057266-20S1
News and More
Related News Releases
No news release information available for 3U19AI057266-20S1
History
No Historical information available for 3U19AI057266-20S1
Similar Projects
No Similar Projects information available for 3U19AI057266-20S1